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that involved biotransformations via both oxidation and 
conjugation. These profiling studies also revealed the pres-
ence of glutathione-derived metabolites providing evidence 
for the production of reactive species by mice administered 
fenclozic acid. Covalent binding to proteins from liver, kid-
ney and plasma was also demonstrated, although this bind-
ing was relatively low (less than 50 pmol eq./mg protein).
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Introduction
Fenclozic acid (2-(4-chlorophenyl)-thiazol-4-ylacetic acid) 
(Myalex) was identified as a promising anti-rheumatic 
in the 1960’s that exhibited no adverse hepatic effects in 
pre-clinical animal tests or initial studies in man (Chalm-
ers et al. 1969a, b). However, whilst doses of 100 mg twice 
daily were well tolerated, doses of 400 mg resulted in a rel-
atively high incidence of jaundice (2 out of 12 subjects in 
Abstract The distribution, metabolism, excretion and 
hepatic effects of the human hepatotoxin fenclozic acid 
were investigated following single oral doses of 10 mg/kg 
to normal and bile duct-cannulated male C57BL/6J mice. 
Whole body autoradiography showed distribution into all 
tissues except the brain, with radioactivity still detectable 
in blood, kidney and liver at 72 h post-dose. Mice dosed 
with [14C]-fenclozic acid showed acute centrilobular hepa-
tocellular necrosis, but no other regions of the liver were 
affected. The majority of the [14C]-fenclozic acid-related 
material recovered was found in the urine/aqueous cage 
wash, (49%) whilst a smaller portion (13%) was eliminated 
via the faeces. Metabolic profiles for urine, bile and faecal 
extracts, obtained using liquid chromatography and a com-
bination of mass spectrometric and radioactivity detection, 
revealed extensive metabolism of fenclozic acid in mice 
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one centre) (Hart et al. 1970). As further cases of jaundice 
and abnormal hepatic function were detected in other trials 
where the 400 mg dose of fenclozic acid was administered 
clinical studies were halted and development was termi-
nated (Alcock 1970). Following the termination of develop-
ment, the pre-clinical data for fenclozic acid were re-exam-
ined and additional work, in a wider range of pre-clinical 
species, was undertaken in an effort to understand the tox-
icity of the compound but to no effect (Alcock 1970). Fen-
clozic acid therefore stands as an example of a drug can-
didate with a good pre-clinical safety profile and good 
efficacy that nevertheless caused serious, dose-related, 
non-idiosyncratic adverse drug reactions (ADR’s) in man. 
Whilst such examples of human-specific ADRs are fortu-
nately rare, they raise questions regarding the effectiveness 
of pre-clinical safety studies that would benefit from a thor-
ough mechanistic investigation of the cause(s) of the toxic-
ity. Recent studies showed that the bioactivation of fenclo-
zic acid in vitro resulted in high levels of covalent binding 
to microsomal preparations supplemented with NADPH 
(Rodrigues et al. 2013), but not UDPGA. So, whilst the 
reactive species responsible for the covalent binding 
proved refractory to identification, in either microsomal 
or hepatocyte-based systems, it seemed likely that oxida-
tive metabolism was responsible for the bioactivation of 
the drug. Indeed, although potentially reactive acyl glucu-
ronides are also formed during the metabolism of fenclozic 
acid in vitro covalent binding in microsomal systems sup-
plemented with UDPGA was lower than systems optimised 
for oxidative metabolism. Further studies in the HRN™ 
(hepatic reductase null) mouse, where hepatic CYP450s are 
inactive and the drug is essentially subject to biotransfor-
mation via acyl conjugation to glucuronic acid and amino 
acid conjugates, showed only low levels of hepatic covalent 
binding (Pickup et al. 2014). More recently, studies in bile 
duct-cannulated rats showed the presence of metabolites 
that were clearly derived from reactive metabolites detoxi-
fied via reaction with glutathione (Martin et al. 2014). 
However, as this study did not employ radiolabelled mate-
rial, it was not possible to determine the contribution of this 
route to the overall metabolic fate of the drug. Here, the 
metabolic fate and hepatic effects of [14C]-fenclozic acid in 




Unlabelled fenclozic acid (2-(2-(4-chlorophenyl)thiazol-
4-yl)acetic acid) was obtained from Compound Man-
agement (AstraZeneca, Alderley Park, Cheshire, UK), 
batch number: AZ10002189-024. [14C]-fenclozic acid 
(2-(2-(4-chlorophenyl)[2-14C]thiazol-4-yl)acetic acid) 
was synthesised and supplied by Isotope Chemistry, 
AstraZeneca, at 237 μCi/mg and a radiochemical purity 
>99%. Ultima Gold scintillation cocktail was purchased 
from Packard Instruments, (Pangbourne, UK). CarboSorb 
oxidiser absorbant and Permafluor E+ scintillant were 
obtained from PerkinElmer (Beaconsfield, UK), whilst 
FLUOTHANE™ was obtained from the AstraZeneca 
Group of Companies. Pierce BCA protein assay kit was 
obtained from Perbio Science (Cramlington, UK). Acetoni-
trile, ethanol, formic acid, hexane, tetrahydrofuran (THF), 
trifluoroacetic acid (TFA) and xylene were all of analyti-
cal grade and supplied by Fisher Scientific (Loughborough, 
UK). Phosphate buffer (pH 7.4) was supplied by AZ media 
(AstraZeneca). All other chemicals or solvents were pur-
chased from commercial suppliers and were of analytical 
grade or the best equivalent.
Animals
Fifteen wild-type mice (strain: C57BL/6J) aged approxi-
mately 8 weeks and weighing between 22.8 and 27.2 g 
were supplied by the AstraZeneca Rodent Breeding Unit, 
Alderley Park. All animal procedures and treatments were 
carried out in accordance with approved animal licenses 
and guidelines issued by the British Home office (Animals 
(Scientific Procedures) Act (1986)).
Study design
All of the mice used in these studies were identified by 
unique tail markings, and acclimatised for 3 days before 
dosing. Mice were kept at room temperature and exposed 
to a 12 h dark/12 h artificial light cycle and an R&M No. 
1 Modified Irradiated diet; potable water was available 
ad libitum. Mice were fasted overnight for 12 h prior to 
oral administration (by gavage) of either [14C]-fenclozic 
acid (10 mg/kg) or phosphate buffer (dosing volume of 
5 mL/kg) the following morning. Phosphate buffer (pH 7.4) 
was used as the vehicle control dose.
Study 1 Semi-quantitative whole body autoradiography 
(QWBA) was performed in order to determine the distribu-
tion of [14C]-fenclozic acid (dose 10 mg/kg and 200 μCi/
kg) following oral administration to 6 male C57BL/6J 
mice. [14C]-Fenclozic acid, specific activity of 237 μCi/mg, 
was diluted with unlabelled fenclozic acid to give material 
with a specific activity of ca. 110 μCi/mg. Unlabelled fen-
clozic acid was dissolved in phosphate buffer (pH 7.4) and 
an appropriate volume of this solution was added to the 
[14C]-fenclozic acid to give a solution at the target-specific 
Arch Toxicol 
1 3
activity 20 μCi/mg and a target concentration of 2 mg/mL. 
After dosing, the mice were housed individually in poly-
carbonate cages with stainless steel mesh inserts, with two 
animals killed at each of the following time points, 6, 24 
and 72 h post-dose by FLUOTHANE™ inhalation. Car-
casses were immediately frozen in a mixture of hexane and 
dry ice at ca. −80 °C. Following freezing, the hind legs and 
tail were removed and each carcass was then embedded 
(left side uppermost) in a block of carboxymethylcellulose 
(ca. 2% in water). The blocks were mounted on the stage 
of a Leica CM3600 cryomicrotome (Leica Microsystems, 
Germany) maintained at approximately −20 °C. Sagittal 
sections (30 µm) were prepared from each animal based on 
the work of Ullberg (Ullberg 1954) to include as many tis-
sues as possible. Sections were then allowed to freeze-dry 
prior to exposure to FUJI phosphor imaging plates (Ray-
tek, Sheffield UK). Sections for imaging were enclosed in 
a light-tight cassette and were exposed for 7 days. After 
exposure, the imaging plates were removed from the cas-
settes under dark room conditions and the plates scanned 
using a FUJI FLA 5000 phosphor imager. Images were 
obtained and quantified using AIDA version 4.22 (Raytest 
UK, Chesterfield UK).
Study 2 A study was undertaken to profile the metabolites 
present in the excreta of male C57BL/6J mice (n = 3) 
[14C]-fenclozic acid following oral administration (dose 
10 mg/kg and 1100, μCi/kg in pH 7.4 phosphate buffer, 
with a dosing volume of 5 mL/kg). [14C]-Fenclozic acid, 
specific activity 237 μCi/mg, was diluted with unlabelled 
fenclozic acid to give material with a specific activity of 
ca. 110 μCi/mg as described above. A further 3 mice were 
administered phosphate buffer to provide a vehicle only 
control dose for histopathology (see below). Mice were 
housed individually in glass metabolism cages and urine, 
faeces and aqueous cage wash were collected from indi-
vidual animals for 72 h post-dose (urine and cage wash 
0–6, 6–12 and 12–24 h then every 24–72 h, faeces were 
collected 0–24, 24–48 and 48–72 h, and samples were col-
lected over dry ice to ensure sample stability), after which 
animals were killed by FLUOTHANE™ inhalation. Fol-
lowing death, the mice were exsanguinated and the blood 
spun for 2 min, at approximately 7800 g and ambient tem-
perature to produce plasma. The liver (with gall bladder 
removed) and kidneys from each animal were removed, a 
small sample of each liver was taken and fixed for histo-
pathology, and the remainder of the liver and kidneys were 
snap-frozen in liquid nitrogen.
Study 3 A third study was undertaken to obtain metabo-
lite profiles for [14C]-fenclozic acid in mouse bile follow-
ing oral administration of 10 mg/kg (200 μCi/kg) to bile 
duct-cannulated C57BL/6J mice. [14C]-Fenclozic acid, spe-
cific activity of 237 μCi/mg, was diluted with unlabelled 
fenclozic acid to give material with a specific activity of 
ca. 110 μCi/mg. Unlabelled fenclozic was dissolved in 
phosphate buffer (pH 7.4), and an appropriate volume of 
this solution was added to the [14C]-fenclozic acid to give 
a solution at the target-specific activity 20 μCi/mg and a 
target concentration of 2 mg/mL. The bile duct-cannulation 
procedure has been described in detail elsewhere (Sarda 
et al. 2014), briefly, within 20 min of dosing 5 animals, 
plus an undosed control mouse, were anaesthetised and, 
following a midline incision (linea alba) the bile duct was 
cannulated and the cannula was exteriorised, with the bile 
then collected into a 0.5 mL Eppendorf tube adjacent to the 
animal. Mice were maintained under anaesthesia until 6 h 
post-dose at which point animals were killed by halothane 
inhalation. As much urine as possible was sampled from 
the bladder at 6 h post-dose, but no attempt was made to 
make a complete collection. Blood was also collected (into 
heparin) and plasma prepared. Samples were frozen on col-
lection and stored at −20 °C until analysis.
Histopathology
Liver samples from mice from Study 2 were fixed in 10% 
neutral-buffered formaldehyde for 5 days before dehy-
drating in increasing concentrations of industrial methyl-
ated spirits (IMS), IMS and xylene (70, 80 and 95%) then 
xylene alone, over a total of 7 h. Dehydrated samples were 
embedded in paraffin wax, after which sections (3 μm 
thick) were prepared and stained with haematoxylin and 
eosin (H&E). Stained sections were observed using light 
microscopy.
Determination of radioactivity in samples
Radioactivity in weighed aliquots of samples of urine, 
bile, aqueous cage wash and plasma was diluted to 1 mL 
with deionised water and mixed with 10 mL of scintilla-
tion cocktail (Ultima Gold). Radioactivity was determined 
by liquid scintillation counting (LSC) using a Packard Tri-
Carb scintillation counter (Pangbourne, UK) for 10 min or 
until 106 counts had accumulated. Samples of faeces, liver 
and kidney were first homogenised in water (1:3 w/v) and 
then combusted using a Packard Oxidiser (model 307). The 
products of combustion were trapped in 9 mL of CarboS-
orb, and then 12 mL Permafluor E+ scintillation cocktail 
were added prior to LSC as described above.
Covalent binding
Liver and kidney samples from each animal from Study 
2 were homogenised by tissue type in water, and indi-
vidual plasma samples were used untreated. The radioac-
tive content for each sample was measured by scintillation 
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counting. The protein content of the homogenates and 
plasma was determined using a Pierce BCA protein assay 
kit, and samples diluted to give 2 mg/mL protein using 
0.1 M phosphate buffer (pH 7.4). Aliquots (200 µL) were 
then placed in the wells of a 96-well plate and 300 µL of 
acetone added, with the samples then agitated for 1 min. 
A further 500 µL acetone was then added and the samples 
agitated again for 1 min to allow the protein to precipi-
tate. The protein pellet was washed with 80% methanol in 
water using a Brandel cell harvester (Gaithersburg, MD). 
The protein concentration and radioactive content of the 
remaining pellet were determined by scintillation counting 
and the extent of covalent binding calculated by difference. 
The statistical significance of the difference was calculated 
using the Student’s t-test function in Microsoft Excel.
Sample preparation for [14C]‑metabolite profiling 
and identification
Urine, faeces, plasma and bile samples were pooled by 
excreta type to include any sample containing greater 
than 1% of the administered dose. The radioactive con-
tent of each pool was determined either by LSC directly 
(urine, and bile) or following combustion (faecal homoge-
nates) as described above. Pre-dose urine and faeces sam-
ples were also prepared in the same way as the post-dose 
samples.
Pooled urine samples were concentrated to ca. 400,000 
dpm/mL under a stream of oxygen-free nitrogen. Bile sam-
ples were pooled to produce a single 0–6 h post-dose sam-
ple and centrifuged at ca. 12,000g for 5 min prior to analy-
sis. The supernatants were transferred to an equal volume 
of ultra-purified distilled water in Waters HPLC 2 mL vials 
for LC/MS analyses. The 6-h plasma samples were pooled 
and a 100 µL aliquot taken and mixed with 300 µL of ace-
tonitrile to precipitate proteins, followed by centrifugation 
at 12,000g for 5 min. The supernatants were transferred to 
an equal volume of ultra-purified distilled water in Waters 
HPLC 2 mL vials to produce a sample for analysis.
The aqueous faecal homogenates were first extracted 
with acetonitrile which was added to each homogenate in 
the ratio 3:1 (vol/weight) and the sample mixed on a rotary 
mixer for 10 min before centrifuging at 3345g for 10 min 
at ambient temperature. The supernatant was removed 
and the radioactive recovery determined by LSC. As only 
78% of the total radioactivity was extracted from the fae-
cal homogenate a further extraction was performed, first 
with 2% (v/v) formic acid in water (3:1vol/wt) followed by 
extraction with tetrahydrofuran (THF) (3:1vol/wt). These 
three extracts gave a combined recovery of 90% of the radi-
oactivity present in the sample. Extracts were combined and 
then concentrated by rotary evaporation at 30 °C, followed 
by further concentration under a stream of oxygen-free 
nitrogen to give samples containing ca. 400,000 dpm/mL. 
The concentrated samples were centrifuged at 25,000g for 
3 min to remove any particulate matter.
Metabolite identification
Structural characterisation of metabolites 
and metabolite profiling by UHPLC‑LTQ‑Orbitrap 
and TopCount radioactivity detection
For the analysis of urine, bile and faeces, a UHPLC-Orbit-
rap profiling system was used similar to that described by 
Martin et al. (2014). Accurate mass structural characterisa-
tion was performed using an LTQ Orbitrap XL mass spec-
trometer (ThermoFisher Scientific, Bremen, Germany) 
fitted with an electrospray source which was operated in 
either positive or negative ion mode. Chromatographic sep-
aration was via a Waters Acquity Ultra high-Performance 
Liquid Chromatography (UPLC) system. The modular 
Waters Acquity system consisted of a binary UPLC pump, 
column oven and autoinjector equipped with a photodiode 
array (PDA) detector with chromatography undertaken 
in a column oven at 50 °C on a Waters BEH C18 column 
(2.1 × 100 mm, 1.8 µm), preceded by a guard filter. Mobile 
phase consisted of 0.1% (v/v) of formic acid in water (elu-
ent A) and 0.1% (v/v) formic acid in methanol (eluent B) 
and was delivered as a gradient at 0.45 mL/min. The gra-
dient elution profile comprised an initial hold at 5% B for 
1 min which was stepped to 20% B at 1.01 min, and a linear 
gradient applied to reach 50% B after 15 min, with a fur-
ther increase to 98% B at 16 min, at which point it was held 
until 17 min, after which the column was re-equilibrated to 
5% B for 2 min, making a total run time of 19 min. Sam-
ples were injected (20 μL) onto the column, and the elu-
ent was diverted to waste for the first 1 min. In line UV 
spectra were acquired over 190–330 nm wavelength range. 
The eluent was split post-column 5:1 (v/v), to an HTC-PAL 
fraction-collector (Presearch Ltd., Basingstoke, UK) for 
collection into 96 deep-well Luma-plates™ coated with 
solid scintillant (Perkin Elmer Ltd., Seer Green, UK) across 
the whole acquisition at a rate of 2.4 s per well. The plates 
were then dried and analysed for radioactivity on a Packard 
HTS-TopCount-NXT (Packard Instruments, Pangbourne, 
UK). Full scan MS data were obtained over the mass range 
of 100 to 1200 Da. Targeted MS2 experiments were con-
ducted in the Orbitrap using higher energy collisional dis-
sociation (HCD) fragmentation, isolation width 3 Da, nor-
malised collision energy 60 eV, and activation time 30 ms. 
All ion trap MSn experiments were performed using colli-
sion induced dissociation (CID), isolation width 3 Da, nor-
malised collision energy 35 eV, and activation time 30 ms. 
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All ions acquired in the Orbitrap were monitored at 7500 
resolution fwhm (full width at half-maximum).
Data analysis
MSn data were collected using Xcalibur v2.1 (Ther-
moFisher Scientific, Bremen, Germany) and TopCount 
radio-scintillation counts were reconstructed as radiochro-
matograms following import into LAURA v4.1.12.89 
(LabLogic Systems Ltd., Sheffield, UK). Components were 
identified as being derived from fenclozic acid by inter-
pretation of a combination of available datasets including 
characteristic isotopic patterns (mono-chlorinated), com-
mon fragments, UV absorbance, 14C incorporation and/or 
accurate mass. Comparisons with pre-dose control samples 
spiked with fenclozic acid were conducted to minimise the 
potential for false positives from system impurities and fil-
ter for endogenous components. All accurate mass meas-
urements including the MS2 fragmentations were within 
±3 ppm of the theoretical accurate mass.
Results
Histopathology
Liver sections treated with haematoxylin and eosin stains 
observed under light microscopy are shown in Fig. 1. Two 
of the three mice dosed with [14C]-fenclozic acid showed 
acute centrilobular hepatocellular necrosis (indicated 
by the arrows in Fig. 1); no other regions were affected. 
The degree of inflammatory cell infiltration was minimal 
and related to the regions of centrilobular necrosis alone. 
Interestingly, in a previous study when fenclozic acid was 
administered to HRN mice at 10 mg/kg (as described in 
Pickup et al. 2014), where hepatic cytochrome P450s are 
non-functional, and there was no evidence of centrilobular 
necrosis, or indeed any other effect on the liver (see Fig. 1).
Semi‑quantitative whole body autoradiography 
(QWBA)
Following oral administration of [14C]-fenclozic acid 
QWBA showed that radioactivity was widely distributed 
into all the tissues of the mouse, with the exception of the 
CNS where only very low levels were detected (Fig. 2). 
The amounts of radioactivity determined from the auto-
radiographs for selected tissues are presented in Table 1, 
together with tissue/blood ratios, illustrating the retention 
of the radioactivity in the tissues compared with circulat-
ing drug-related material. The highest concentrations of 
radioactivity were detected in the blood, liver and kid-
ney. The results of the QWBA study clearly showed that 
radioactivity was still detectable in the tissues of animals 
72 h post-dosing.
Covalent binding of radioactivity to protein
The retention of radioactivity in the liver and kidneys of 
these mice as determined by QWBA was similar, with 
0.63 ± 0.10 (SD) % of that administered remaining in 
the liver and 0.55 ± 0.10 (SD) % in the kidneys at 72 h 
post-dose. Further studies were therefore performed on 
plasma, liver and kidney samples to determine whether this 
relatively long-retained radioactivity was due to covalent 
binding (CVB) to cellular macromolecules. These stud-
ies showed CVB amounting to ca. 18, 40 and 10 pg/mg 
protein detected for liver, kidney and plasma, respectively 
(Table 2), which was slightly higher than that observed 
for these tissues in HRN mice given an equivalent dose 
in our previous study (ca. 13, 26 and 3 pg/mg protein for 
liver, kidney and plasma, respectively) (Pickup et al. 2014). 
Interestingly, these quantities of CVB were approximately 
an order of magnitude greater than those observed for the 
idiosyncratic liver toxin diclofenac (see Boelsterli 2003) 
dosed at 10 mg/kg to C57BLl/6J mice where the extent of 
covalent binding (at 24 h) were ca. 1.65, 3.37 and 1.42 pg/
mg for liver, kidney and plasma, respectively, (the equiva-
lent figures for diclofenac in the HRN mouse were 1.92, 
1.86 and 7.97 pg/mg) (Pickup et al. 2012).
Metabolite profiles of [14C]‑fenclozic acid in urine, 
faeces and bile
Following oral administration of [14C]-fenclozic acid at 
10 mg/kg to C57BL/6J mice, the majority (ca. 79%) of the 
radioactivity recovered by 72 h post-dose was present in 
the urine/cage wash (the radioactivity in the cage wash was 
presumed to be urinary in origin). UHPLC analysis with 
radioactivity and mass spectrometric detection revealed the 
presence of a number of drug-related peaks corresponding 
to fenclozic acid itself, the acyl glucuronide, glycine and 
taurine conjugates (M10, M14 and M13, respectively) and 
an ether glucuronide (M20) (Supplementary data Figure 
S1A). The mass spectra for the acyl conjugates were previ-
ously described following studies in HRN mice and the rat 
(Pickup et al. 2014; Martin et al. 2014). Whilst urine repre-
sented the major route for the elimination of [14C]-labelled 
fenclozic acid-related material ca. 21% of the recovered 
dose was found in the faeces over the 72 h collection 
period. In contrast to our previous studies on HRN mice, 
solvent extraction of faeces to recover the excreted fen-
clozic acid metabolites required relatively aggressive con-
ditions to achieve efficient extractions of radiolabel. The 
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combination of harsh extraction conditions and poor recov-
ery led to concerns that the resulting radio-UHPLC profile 
(Supplementary data Figure S1B) may be distorted by the 
degradation of labile metabolites. These concerns led us 
to undertake a study in bile duct-cannulated mice, which 
were also sampled for blood plasma and urine as well as 
bile at 6 h post-dose. Urine, bile and plasma were profiled 
using UHPLC analysis with radioactivity and mass spec-
trometric detection (representative reconstructed TopCount 
radiochromatograms for urine and bile are given in Fig. 3a, 
b, respectively). Analysis of plasma revealed that the major 
circulating component was [14C]-fenclozic acid itself, with 
traces of the glycine conjugate also detected (Supplemen-
tary data Figure S2). As illustrated in Fig. 3, the urinary 
and biliary profiles were composed of unchanged fenclo-
zic acid together with a range of oxidised and conjugated 
(both ether and acyl) metabolites. The profiles of both 
urine and bile were, however, dominated by acyl conju-
gates. For urine from bile duct-cannulated mice, as seen in 
the non-cannulated animals (Supplementary Figure S1A), 
the acyl glycine conjugate (M14) was the most abundant 
accounting for ca. 40% of the total radioactivity, but acyl 
taurine (M13, 13.3%), glucuronide (M10, 4.5%) and glu-
tamyl (M12, 2.5%) conjugates were also noted, as well as 
Fig. 1  Photomicrographs of representative samples of the livers from 
wild type (WT) and hepatic cytochrome P450 reductase null (HRN) 
mice treated with a single 10 mg/kg oral dose of [14C] fenclozic acid 
(see Pickup et al. 2014). a, b HRN mice dosed with vehicle control, 
c, d HRN mice dosed with [14C]-fenclozic acid, and e, g WT mice 
dosed with [14C]-fenclozic acid. The images illustrate the absence of 
drug-induced toxicity in HRN mice in comparison with WT mice. e, 
f Representative of the pathology seen in WT mice following admin-
istration of [14C]-fenclozic acid with prominent centrilobular necro-
sis and little inflammatory cell infiltration (indicated by the arrows). 
g Taken from an animal also given [14C]-fenclozic acid but which 
showed no toxicity; this illustrates the variation in toxicity observed. 
Original objective lens magnification for a, c, e, g ×10 whereas b, d, 
f ×20. CL centrilobular and P periportal. Livers exposed to haema-
toxylin and eosin stains
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an ether glucuronide of an oxygenated metabolite (M22, 
14.7%), which between them accounted for more than 75% 
of the total radioactivity in the eluent (see Fig. 3a; Table 3). 
Oxidative decarboxylation, leading to a side-chain short-
ened metabolite (M8, 8.1%) was also observed with its’ 
corresponding glycine conjugate (M9, 1.5%) representing 
a minor product. Of particular interest, however, was the 
presence of a trace amount of an oxygenated cysteinegly-
cine metabolite (M16), amounting to ca. 0.6% of the total 
radioactivity, indicative of reactive metabolite formation. 
Bile metabolite profiles (Fig. 3b), in contrast to urine, were 
dominated by the presence of large amounts of the taurine 
conjugate (M13, ca. 43% of total radioactivity) and fen-
clozic acid (11%). Glycine (M14, 3.6%), carnitine (M11, 
1.2%) and ether glucuronide (M22, 2.5%) conjugates were 
also detected, but the glutamyl, acyl glucuronide and side-
chain shortened metabolites seen in urine were absent from 
bile. The biliary profile, however, provided further evidence 
of reactive metabolites in the form of a cluster of metabo-
lites formed from the oxygenated glutathione (M18, 4.2%) 
the cysteineglycine (M24, 1.9%) and oxygenated cysteine-
glycine (M16, 5.4%) metabolites (Fig. 3b; Table 3) which 
between them accounted for over 11% of the total radioac-
tivity in the radio chromatogram. Bile duct-cannulated rats 
administered unlabelled fenclozic acid also showed this 
type of metabolite and detailed descriptions of the mass 
spectrometric data for these metabolites are described in 
detail in this previous work (Martin et al. 2014). 
Discussion
As indicated in the introduction, despite the best efforts 
of those involved at the time, the cause of the hepatoxic-
ity observed in human volunteers in clinical trials, but not 
in any of the pre-clinical species, defied explanation at 
the time of fenclozic acids’ withdrawal from development 
(Alcock 1970). More recently, in vitro investigations pro-
vided clear evidence of high levels of NADPH-dependant 
CVB to hepatic microsomes and hepatocytes (Rodrigues 
et al. 2013) when [14C]-fenclozic acid was incubated in the 
presence of microsomes, but only when supplemented with 
NADPH (125.8 + 20.1, 70.1 + 19.8 and 38.5 + 6.8 pg 
equiv./mg protein for human, dog and rat, respectively) 
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Fig. 2  Autoradiography images of C57BL/6J mice following a sin-
gle 10 mg/kg oral dose of [14C]-fenclozic acid. Fenclozic acid-related 
material was well distributed into all tissues with the exception of the 
central nervous system and still remained in tissues at 72 h post-dose
Table 1  Radioactivity in liver, 
kidney and blood/tissue ratios 
via QWBA
The mean (n = 2) radioactive content (dpm/g) of selected tissues in of C57BL/6J mice, 6, 24 and 72 h after 
a single 10 mg/kg oral dose of [14C]-fenclozic acid
WT 6 h 24 h 72 h
dpm/g Tissue/blood dpm/g Tissue/blood dpm/g Tissue/blood
Blood 3150,670 1.00 1266,494 1.00 145,195 1.00
Brain 81,217 0.03 27,020 0.02 2143 0.01
Kidney cortex 3429,797 1.09 1565,700 1.24 298,993 2.06
Kidney medulla 1283,496 0.41 494,144 0.39 86,467 0.60
Liver 2187,659 0.69 626,466 0.49 123,707 0.85
Table 2  Covalent binding of fenclozic acid-related material in 
organs or plasma of C57BL/6J mice 72 h after a single 10 mg/kg oral 
dose of [14C]-fenclozic acid
Each sample is the mean ± SD of 3 determinations/animal/tissue
Animal pmol equiv/mg protein
Liver Kidney Plasma
1 10.70 ± 0.32 31.03 ± 1.20 7.74 ± 0.71
2 23.49 ± 1.58 48.49 ± 2.98 12.85 ± 1.07
3 18.79 ± 1.42 40.54 ± 3.28 8.09 ± 1.11
Mean ± SD 17.66 ± 6.47 40.02 ± 8.74 9.56 ± 2.85
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74.9 + 13.6 pg equiv./mg protein for dog, rat and human, 
respectively). That investigation also demonstrated that 
CVB to microsomes was reduced in the presence of glu-
tathione or cysteine, suggesting that oxidative metabolism 
to a soft nucleophile was responsible. However, despite 
this strong evidence of oxidative metabolism in the in vitro 
studies, no likely metabolites were detected in incubations 
with either microsomes or hepatocytes, and ‘trapping’ 
experiments for reactive metabolites were also negative. In 
the present study, a histopathological examination detected 
effects on the liver in mice following a single oral dose of 
10 mg/kg. Thus, dosing with [14C]-fenclozic acid resulted 
in acute centrilobular hepatocellular necrosis (Fig. 1) for 
two out of three animals. However, inflammatory cell infil-
tration was minimal and was seen only in the areas affected 
by centrilobular necrosis with no other regions affected. 
The minimal degree of inflammatory cell infiltration could 
have been due to the protective anti-inflammatory effects 
of the drug or it could be that the acuteness of the lesion 
had not allowed time for inflammation to take place (or 
indeed a combination of the two). As noted earlier, when 
fenclozic acid was administered at the same dose as in 
the present study to HRN mice where hepatic cytochrome 
P450s were non-functional, there was no evidence of any 
similar necrosis (Pickup et al. 2014). It is therefore tempt-
ing to ascribe this type of effect to P450-related produc-
tion of toxic metabolites. The present study has shown that 
CVB to proteins also occurs in vivo with the highest levels 
seen for kidney followed by liver and plasma. The levels of 
CVB noted for C57BL/6J mice in the liver 72 h post-dose 
were 17.66 ± 6.47 pmol equiv/mg protein (whilst for the 
HRN animals the equivalent figure was 13.43 ± 3.35 pmol 
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Oxidation and ether glucuronidation (M22)










































































oxidative decarboxylation and Glycine 
conjugation (M9)
1.45 ND
Values in bold type denote peak corresponding to >10% total chromatogram radioactivity
Assigned metabolites corresponded to 89.8 and 84.9% of the total radioactivity observed for urine and bile chromatograms, respectively
Highlighted yellow bonds on structures indicate likely sites of metabolism
ND Not detected
* Masses correspond to 12C isotope ion
** Metabolite nomenclature is in concordance with Martin et al. (2014) where applicable
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equiv/mg protein) (Pickup et al. 2014). As noted earlier 
these levels of CVB were much higher than those seen for 
an equivalent dose of the NSAID diclofenac (Sarda et al. 
2012) which is a well-known idiosyncratic hepatotoxin in 
humans (Boelsterli 2003). The lack of metabolites seen 
in in vitro incubations is in stark contrast to the situa-
tion observed in vivo, both during the drugs development 
(Foulkes 1970) and, more recently in studies undertaken 
in HRN mouse (Pickup et al. 2014), where extensive con-
jugation was seen, and the bile duct-cannulated rat (Mar-
tin et al. 2014) where biotransformation to both oxidised 
and conjugated metabolites were detected. The metabolite 
profiles for fenclozic acid obtained in the present study in 
C57BL/6J mice also show that the bulk of the metabolites 
excreted in both urine and bile are formed through direct 
metabolism of the carboxylic acid moiety to form conju-
gates, particularly glycine (M14) and taurine (M13). How-
ever, there was also clear evidence of significant oxidative 
metabolism on the chlorobenzene ring (followed by conju-
gation to an ether glucuronide) (M22), as well as a small 
amount of oxidative decarboxylation (as previously seen in 
the mouse for diclofenac (Sarda et al. 2012). Interestingly, 
as well as in vivo covalent binding to proteins, metabolites 
detected in the form of the oxygenated cysteineglycine 
metabolite (M16) were seen in both urine and bile with, in 
addition, the oxygenated glutathione (M18) and cysteineg-
lycine (M24) metabolites detected in bile, provide further 
evidence for the formation of reactive metabolites, and 
their detoxication by glutathione, in the form of soft elec-
trophiles. These glutathione-derived metabolites, particu-
larly those excreted in the bile, between them accounted for 
a significant portion of the dose (ca. 11%). This relatively 
large contribution of metabolites linked to reactive metabo-
lite production should perhaps be contrasted with the com-
plete absence of detectable quantities of any downstream 
metabolites of glutathione conjugates detected in the bile of 
mice dosed at 10 mg/kg with diclofenac (Sarda et al. 2014). 
It seems increasingly likely therefore that the toxicity of 
fenclozic acid observed in humans was, at least in part, 
the result of the formation of hepatotoxic reactive metabo-
lites as the products of P450-related oxidative metabolism. 
However, despite the evidence for bioactivation to reactive 
metabolites indicated in previous studies in the rat (Martin 
et al. 2014) and in this investigation in the mouse, only lim-
ited effects were observed on the livers of the latter here, 
and no effects were reported in the many pre-clinical toxi-
cology studies performed during the drugs’ development. 
This might reflect differences in the metabolic flux through 
the P450-toxication pathway(s) versus the detoxication 
alternatives provided by conjugation in animals compared 
to humans exposed to the drug with the proportion of the 
dose undergoing metabolic activation being much higher 
in the latter. Such species differences can have profound 
effects as we have recently shown in the case of acetami-
nophen where, despite being dosed to the cynomolgus 
monkey at significant multiples of that needed to cause 
hepatotoxicity in humans, produced no adverse effects on 
the liver (Yu et al. 2014). This lack of toxicity is despite 
the cynomolgus monkey possessing a CYP2E1 enzyme 
with very high structural homology to that of humans and, 
based on in vitro results, did show CVB for acetaminophen 
(Martignoni et al. 2006). However, in vivo, the cynomolgus 
monkey preparations showed little evidence for quinone 
imine production, with the majority of the drug apparently 
metabolised via conjugation (primarily to the glucuronide). 
A similar explanation, related to the relative flux of fenclo-
zic acid through the various metabolic reactions may also 
account for differences in DILI seen between humans and 
the various pre-clinical animal species in which it has been 
studied.
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